Overview

• In a synthesis of 14 randomized trials involving over 100,000 participants, researchers reported strong protection for those at highest risk of severe RSV illness.
• Among older adults, prefusion RSV vaccines reduced RSV-related lower respiratory tract disease by 77% and acute respiratory disease by 67%.
• Maternal vaccination cut infants’ need for medical care for RSV lower respiratory tract disease by 54%, severe disease by 74%, and hospitalizations by 54%.
• Across age groups, trials showed little to no difference in serious adverse events between vaccinated and unvaccinated participants, with real-world effectiveness and safety studies in progress and an ECDC update planned in the coming weeks.
• A BMJ Open analysis in England found no association between vaccination in pregnancy and adverse perinatal outcomes, while noting uneven uptake with over two million doses given overall, 337,000 to pregnant women, and the lowest coverage in London.